Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Net Income towards Common Stockholders (2016 - 2025)

Sunshine Biopharma's Net Income towards Common Stockholders history spans 12 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 0.8% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$6.0 million, up 6.9%, while the annual FY2025 figure was -$6.0 million, 16.39% down from the prior year.
  • Net Income towards Common Stockholders reached -$2.1 million in Q4 2025 per SBFM's latest filing, down from $295951.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $667116.0 in Q4 2021 to a low of -$23.5 million in Q4 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$2.8 million, with a median of -$1.4 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 3624.47% in 2022, then surged 124.71% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then grew by 0.8% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Net Income towards Common Stockholders are -$2.1 million (Q4 2025), $295951.0 (Q3 2025), and -$3.0 million (Q2 2025).